Rui Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rui Cheng has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Jianfa Zhang
Center for Molecular Metabolism, Nanjing University of Science and Technology, Nanjing, China
3 shared publications Wenhao Ge
Center for Molecular Metabolism, Nanjing University of Science and Technology, Nanjing, China
2 shared publicationsXi Xu
Center for Molecular Metabolism, Nanjing University of Science and Technology, Nanjing, China
2 shared publicationsYang Zhao
2 shared publicationsZhao Ding
2 shared publications- Changchang Kong
Center for Molecular Metabolism, Nanjing University of Science & Technology, Nanjing 210094, China
1 shared publication
Latest Publications
- 6 May 2022
- Published by Elsevier in Carbohydrate Polymers
- Vol. 291, 119561
The structure and flocculation characteristics of a novel exopolysaccharide from a Paenibacillus isolate
- 6 May 2022
- Published by Elsevier in Carbohydrate Polymers
- Vol. 291, 119561
The structure and flocculation characteristics of a novel exopolysaccharide from a Paenibacillus isolate
- Open Access
- 13 October 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Riclinoctaose Attenuates Renal Ischemia-Reperfusion Injury by the Regulation of Macrophage Polarization
Renal ischemia-reperfusion injury is a major trigger of acute kidney injury and leads to permanent renal impairment, and effective therapies remain unresolved. Riclinoctaose is an immunomodulatory octasaccharide composed of glucose and galactose monomers. Here we investigated whether riclinoctaose protects against renal ischemia-reperfusion injury. In mice, pretreatment with riclinoctaose significantly improved renal function, structure, and the inflammatory response after renal ischemia-reperfusion. Flow cytometry analysis revealed that riclinoctaose inhibited ischemia-reperfusion-induced M1 macrophage polarization and facilitated M2 macrophage recruitment into the kidneys. In isolated mouse bone marrow-derived macrophages, pretreatment with riclinoctaose promoted the macrophage polarization toward M2-like phenotype. The inhibitor of Nrf-2/HO-1 brusatol diminished the effects of riclinoctaose on macrophage polarization. In mice, intravenous injection with riclinoctaose-pretreated bone marrow-derived macrophages also protected against renal ischemia-reperfusion injury. Fluorescence-labeled riclinoctaose specifically bound to the membrane of macrophages. Interfering with mDC-SIGN blocked the riclinoctaose function on M2 polarization of macrophages, consequently impairing the renoprotective effect of riclinoctaose. Our results revealed that riclinoctaose is a potential therapeutic agent in preventing renal ischemia-reperfusion injury.
- 13 October 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Open AccessRiclinoctaose Attenuates Renal Ischemia-Reperfusion Injury by the Regulation of Macrophage Polarization
Renal ischemia-reperfusion injury is a major trigger of acute kidney injury and leads to permanent renal impairment, and effective therapies remain unresolved. Riclinoctaose is an immunomodulatory octasaccharide composed of glucose and galactose monomers. Here we investigated whether riclinoctaose protects against renal ischemia-reperfusion injury. In mice, pretreatment with riclinoctaose significantly improved renal function, structure, and the inflammatory response after renal ischemia-reperfusion. Flow cytometry analysis revealed that riclinoctaose inhibited ischemia-reperfusion-induced M1 macrophage polarization and facilitated M2 macrophage recruitment into the kidneys. In isolated mouse bone marrow-derived macrophages, pretreatment with riclinoctaose promoted the macrophage polarization toward M2-like phenotype. The inhibitor of Nrf-2/HO-1 brusatol diminished the effects of riclinoctaose on macrophage polarization. In mice, intravenous injection with riclinoctaose-pretreated bone marrow-derived macrophages also protected against renal ischemia-reperfusion injury. Fluorescence-labeled riclinoctaose specifically bound to the membrane of macrophages. Interfering with mDC-SIGN blocked the riclinoctaose function on M2 polarization of macrophages, consequently impairing the renoprotective effect of riclinoctaose. Our results revealed that riclinoctaose is a potential therapeutic agent in preventing renal ischemia-reperfusion injury.
- Open Access
- 1 July 2021
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 297 (1) , 100846
An insulin-independent mechanism for transcriptional regulation of Foxo1 in type 2 diabetic mice
- 1 July 2021
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 297 (1) , 100846
Open AccessAn insulin-independent mechanism for transcriptional regulation of Foxo1 in type 2 diabetic mice